The US approval late last year of the blood thinner Eliquis made it the third blood-thinner pill substitute for come online within the last three years, which have proven to be as or even more effective as the old go-to warfarin, with lower rates of brain hemorrhaging and fewer blood vessels tests required to get the dosing right . New anticoagulation antidotes could possibly be on the true way. This pact comes on top of a similar partnership announced in November 2012 between Portola and the makers of Eliquis, Bristol-Myers Pfizer and Squibb, both based in New York.

In their research of mice, Drs. Thorpe and Xianming Huang, assistant professor of pharmacology in the Harold C. Simmons Comprehensive Cancer Center, found the antibody substance 3G4 was effective as a vascular targeting agent when used in combination with docetaxel. VTAs are created to discover and destroy blood vessels within cancerous tumors, reducing off their blood supply. Specifically, mice with human breasts tumors treated with 3G4 and docetaxel acquired a 93 % decrease in overall tumor development. The injected breast cancer cells stimulated the growth of tumor colonies in the lungs also, and the drug mixture reduced the common number of these colonies by 93 %, with half of the mice not developing any lung tumors.